#Checkmate 227 plus

With chemotherapy was observed regardless of NSCLC histology. 1 Among responders, 31%, 13%, and 0% remained inĪmong patients who progressed on NIVO + IPI versus chemotherapy, 7% versus 40% (PD-L1 ≥1%), andĩ% versus 33% (PD-L1 <1%), received subsequent immunotherapy. 1 At 4 years, 12% (NIVO + IPI), 7% (NIVO + chemotherapy), andĠ% (chemotherapy) remained progression-free. 1 In patients with PD-L1 <1%, OS HR for NIVO + IPI versusĬhemotherapy was 0.64 (95% CI, 0.51-0.81) and 4-year OS rates were 24% (NIVO + IPI), 13% (NIVO +Ĭhemotherapy), and 10% (chemotherapy). In an exploratory analysis in patients with PD-L1 ≥50%, 4-year OS rates were 37% (NIVO + IPI), 26% 1 Among responders,ģ4%, 30%, and 7% remained in response, respectively. 1 At 4 years,ġ4% (NIVO + IPI), 10% (NIVO), and 4% (chemotherapy) remained progression-free. 1 Four-year OS rates were 29% (NIVO + IPI), 21% (NIVO), and 18% (chemotherapy). Patients with PD-L1 ≥1%Ĭontinued to show a durable OS benefit with NIVO + IPI compared with chemotherapy (HR, 0.76 95% CI,Ġ.65-0.90). Years beyond the protocol-specified end of immunotherapy treatment.

The primary end point was OS with NIVO + IPI compared with chemotherapy inĪfter minimum follow-up of 49.4 months (database lock, February 18, 2021), patients were at least 2 <1% were randomized to receive NIVO + IPI, NIVO (360 mg every 3 weeks) + chemotherapy, orĬhemotherapy alone.

#Checkmate 227 plus

≥1% were randomized to receive NIVO at a dose of 3 mg/kg every 2 weeks plus IPI at a dose of 1 mg/kgĮvery 6 weeks, NIVO alone (240 mg every 2 weeks), or chemotherapy. Patients were stratified by histology: squamous and nonsquamous. 1Īdults with previously untreated stage IV or recurrent NSCLC, no known EGFR or ALK alterations, andĮastern Cooperative Oncology Group performance status of 0 or 1 were enrolled in CheckMate-227. 1 At the American Society of Clinical Oncology 2021 annual meeting, researchers reported updated results from the CheckMate-227 study with 4 years’ minimum follow-up. 1 Three-year OS rates were 34% compared with 15% in patients with PD-L1 expression levels <1% (HR, 0.64 95% CI, 0.51-0.81). In this study, the 3-year OS rates were 33% compared with 22% in patients with PD-L1 expression levels of ≥1% (hazard ratio, 0.79 95% confidence interval, 0.67-0.93). Patients with advanced non–small-cell lung cancer (NSCLC) in CheckMate-227 Part 1. Overall survival (OS) benefit compared with chemotherapy regardless of tumor PD-L1 expression in The combination of nivolumab (NIVO) and ipilimumab (IPI) was shown to provide durable long-term Survival benefit compared with chemotherapy in patients with advanced non–small-cell lung cancer Gastrointestinal Cancer Monthly MinutesĪfter 4 years of follow-up, nivolumab combined with ipilimumab provides durable, long-term.

Advances in Dual Immunotherapy Cancer Treatments.